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Summary Several Methotrexate (MTX)-resistant sublines of the osteogenic sarcoma cell line 791T were
derived by continuous selection in the presence of MTX and 12-O-tetradecanoylphorbol-13-acetate (TPA).
Studies including assays of the uptake and binding of [3H]MTX and fluoresceinated-MTX, determined that
these sublines showed diminished MTX transport, and that none of them appeared to overproduce the
MTX-target enzyme dihydrofolate reductase.
Conjugates of the anti-791T monoclonal antibody 791T/36 linked to MTX via human serum albumin
(HSA) were prepared by Dr M.C. Garnett. These were cytotoxic selectively for cells bearing the 791T/36-
defined antigen (gp72), and were found to be as cytotoxic to most of the MTX-resistant 791T sublines as they
were to parental 791T cells. Furthermore, an anti-MTX/anti-gp72 bispecific antibody 516 augmented the
cytotoxicity of HSA-MTX conjugate to the MTX-resistant 791T variant R120 apparently as efficiently as for
parental 791T cells.
It is suggested that acquired drug resistance caused by deficient transport mechanisms may be partially or
wholly overcome by targeting the drug to a readily-internalised cell surface antigen.
One of the major obstacles to successful chemotherapy of
tumours is the development of drug resistance. This is a
problem commonly associated with treatment using the clas-
sical folate antagonist methotrexate (MTX). MTX acts by
inhibiting dihydrofolate reductase (DHFR), so depleting tet-
rahydrofolate, an essential cofactor in a number of one-
carbon transfer reactions, including the biosynthesis of
thymidylate required for DNA synthesis.
Mechanisms of acquired resistance to MTX include defec-
tive MTX transport (Sirotnak et al., 1981), overproduction of
DHFR (Alt et al., 1976) with a corresponding amplification
of the DHFR gene (Alt et al., 1978), altered DHFR with
decreased affinity for MTX (Jackson & Niethammer, 1977)
or increased activity (Dedhar et al., 1985), and decreased
ability to polyglutamylate MTX (Cowan & Jolivet, 1984).
In the case of resistance due to altered transport of MTX,
a number of approaches to overcoming resistance have been
suggested. These include: (a) the use of antifolates that do
not use the reduced folate/MTX transport system, such as
the lipophilic drug trimetrexate (Kamen et al., 1984); (b) the
use of high dose MTX with leucovorin rescue, as at high
concentrations MTX is able to enter cells by passive diffusion
(Hill et al., 1982); (c) the use of lipophilic esters of MTX
(Rowsowsky et al., 1980); (d) attempting to bypass the MTX
transport system by the use of MTX encapsulated in
liposomes (Kosloski et al., 1978), or conjugated to carriers
such as albumin (Chu et al., 1981) and poly-(L)-lysine (Shen
& Ryser, 1979).
Another possible way of circumventing MTX-resistance
due to transport deficiency could be the use of MTX con-
jugated to monoclonal antibodies, or antibody sub-units,
which recognise tumour associated antigens. By allowing
MTX to enter cells via an antibody-mediated route, the
MTX transport system may be bypassed, and the transport
defect avoided. This approach was investigated by deriving a
number of MTX-resistant, transport-defective variant sub-
lines of an osteogenic sarcoma cell line (791T), and assessing
their sensitivities to monoclonal antibody-MTX conjugates.
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Materials and methods
Cell lines
The human osteogenic sarcoma tumour cell line 791T was
grown in monolayer cultures in 90 mm diameter plastic petri
dishes (Cell-Cult, Sterilin Limited, Hounslow) in Eagles
Minimal Essential Medium (EMEM, Flow Laboratories,
Rickmansworth) supplemented with 10% heat-inactivated
newborn calf serum (NBCS, Gibco Limited, Basingstoke,
Hants).
The MTX-resistant sublines of the 791T line were grown in
EMEM plus 10% NBCS, with added MTX at a concentra-
tion in which the subline was able to grow at the same rate
as the parental cell line.
The MTX-resistant Chinese hamster ovary cell line M3000
was kindly provided by Dr A. Kinsella (Paterson Labor-
atories, Christie Hospital and Holt Radium Institute, Man-
chester, UK), and was grown in Dulbeccos MEM with 10%
foetal calf serum (Sera-lab Ltd., Sussex, UK).
Cells were harvested with a mixture of 0.25% trypsin and
0.5% EDTA for use in in vitro assays.
Monoclonal antibodies
Monoclonal antibody 791T/36 is a murine IgG2b antibody,
obtained from a hybridoma produced by fusing spleen cells
from a mouse immunised against osteogenic sarcoma cell line
791T, with P3-NSl-Ag-4 mouse myeloma (Embleton et al.,
1981). This antibody was affinity purified from ascites fluid
on a protein A column eluted with 3 M sodium thiocyanate.
This antibody recognises a 72,000 molecular weight glycop-
rotein, termed gp72 (Price et al., 1983). The 791T/48
antibody was also of the IgG2b subclass, and was raised
against 791T cells, but it recognises an epitope on 791T cells
separate from that detected by 791T/36 (Embleton et al.,
1981).
The 516 bispecific antibody which recognises both the
791T/36-defined gp72 antigen, and MTX conjugated to pro-
teins including HSA was produced by fusing spleen cells
from MTX immunised mice with 791T/36-producing hyb-
ridoma cells (Pimm et al., 1990), and was provided by Dr
M.V. Pimm of this department.
Chemicals
Methotrexate in alkaline saline (Cyanamid GB; Lederle
Laboratories, Gosport, Hants, UK) was diluted to a stock
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solution of 1 mg ml-' in PBS. [3', 5', 7-3H]methotrexate,
sodium salt, was purchased from Amersham International
plc, Amersham, Bucks, UK.
Conjugates
MTX-HSA-791T/36 conjugates were prepared by the method
of Garnett and Baldwin (1986). Briefly, MTX was conjugated
to HSA by reacting excess MTX and HSA with ethyl car-
bodiimide. This reaction produced some polymerised HSA-
MTX which was removed by size exclusion chromatography.
791T/36 antibody was iodoacetylated by reacting the
antibody with N-succinimidyl iodoacetate. Reduction of
HSA-MTX with dithiothreitol activated the sulphydryl group
and, after desalting, the reduced HSA-MTX was reacted with
the iodoacetyl-substituted antibody.
Unreacted products were removed by gel filtration on
Sephadex G-25 column. All conjugates were supplied by Dr
M.C. Garnett, Cancer Research Campaign Laboratories,
University of Nottingham.
Derivation ofMTX-resistant sublines
MTX-resistant sublines of the 791T line were derived by a
method similar to that described by Varshavsky (1981). Cells
were plated in 90 mm diameter petri dishes at 5 x I05 cells
per dish in 10 ml of EMEM/10% NBCS, and were incubated
in the presence of MTX initially at a dose of 10 ng ml-' (the
approximate IC50 value of MTX for 791T). The tumour
promoter 12-O-tetradecanoylphorbol-1 3-acetate (TPA,
Sigma) was added at 0.1 tg ml-'. Cells were grown to
confluence and were then subcultured into a doubled concen-
tration of MTX in the continuous presence of TPA. This
stepwise selection procedure was continued until the max-
imum dose of MTX was reached in which the cells could
grow at the same rate as parental cells. The 791T sublines are
denoted R120, R160E, R250 and R500.
Cytotoxicity tests
Cytotoxicity was assayed by the ability of MTX or con-
jugates to inhibit the replication and survival of cells in
96-well microtiter plates, survival being measured by the
incorporation of [75Se]selenomethionine (Embleton et al.,
1983). This assay has been shown to give results qualitatively
equivalent to those obtained using clonogenic assays with
MTX and MTX-conjugates (Garnett et al., 1983; Embleton
et al., 1984; Embleton & Garnett, 1985).
The cytotoxicity of HSA-MTX targeted by 516 bispecific
antibody was tested by [75Se]selenomethionine microcyotox-
icity assay with some modifications. Cells were plated at
1 x I04 per well of a 96-well microtitre plate in 100 sl of
growth medium. Dilutions of 516 antibody were added in
50fl of medium, and the cells were incubated with antibody
for 30 min. After this period, HSA-MTX was added to each
well in 50fil of medium to give a final concentration of
250 ngml' in terms of MTX content. HSA-MTX is much
less cytotoxic than free MTX, and this dose was completely
non-toxic to both 791T and R120 cells when administered
alone (data not shown). Following 24 h incubation, the cells
were labelled overnight with ['5Se]selenomethionine (0.1 sCi
per well).
Inhibition ofcytotoxicity by 'cold' antibody
The effect of free antibody on the cytotoxicity of conjugates
was tested using a modification of the [75Se]selenomethionine
incorporation assay. Fifty 1ll of antibody at various dilutions
in EMEM plus 10% NBCS was added to target cells in
100gl of the same medium. To this were added 50pl of
medium containing conjugate or MTX at a fixed dose (see
text). Following 24 h incubation, the cells were labelled over-
night with [75Se]selenomethionine (0.1 fiCi per well).
Assayfor antigenicity
For assessment of the level of expression of antigen defined
by the 791T/36 monoclonal antibody, cells were subjected to
an indirect flow cytofluorimetric assay. 2 x 105 cells were
incubated with 200 il of monoclonal antibody at 10 igml'l
for 30 min on ice. Following washing, cells were incubated
with fluorescein isothiocyanate-labelled rabbit anti-mouse
immunoglobulin for a further 30 min on ice. Samples were
assayed on a fluorescence activated cell sorter (FACS IV;
Becton-Dickinson, Sunnyvale, CA.) at 488 nm. Mean linear
fluorescence readings were proportional to antigen expression
(Roe et al., 1985).
Transport studies
The MTX-transport properties of the MTX-resistant variants
were studied using a modified version of that described by
Niethammer and Jackson (1975). Cells growing in monolayer
were harvested during logarithmic growth phase using
trypsin/EDTA, and were pelleted and washed twice. Cells
were resuspended to 2 x 107 ml-' in Dulbecco's PBS (Oxoid),
pH 7.2, at 37°C, in 30 ml plastic tubes. Suspensions were
maintained at 37°C with gentle continuous shaking. Purified
[3H]MTX (Amersham International plc, Amersham) was
added to the suspensions at time zero to give a final extracel-
lular MTX concentration of 1 t4M. Aliquots, each of 0.5 ml,
were withdrawn at intervals up to 60 min. These samples
were blown into ice-cold PBS in Eppendorf tubes to stop the
uptake of MTX. The samples were maintained on ice until
all samples had been collected. The cells were pelleted in a
microfuge and washed twice with ice-cold PBS. Cells were
pelleted in a microfuge and washed twice with ice-cold PBS.
Cells were pelleted again, and then lysed by resuspension in
1 ml of distilled water, and incubation at room temperature
for 30 min. Samples were transferred to glass scintillation
vials. 10 ml of scintillant (Emulsifier-Safe, Packard) was
added, and radioactivity was determined using a liquid scin-
tillation counter. Data are shown as cpm per 107 cells.
Determination ofDHFR levels
The method used was based on that of Kaufman et al.
(1978), and used fluoresceinated-MTX (Fluo-MTX) to quan-
titate DHFR. Fluo-MTX (Molecular Probes, Eugene, OR,
USA) was diluted to 1 mM in 10 mM ammonium hydroxide
and stored at - 70C. Cells were maintained in monolayer
culture in the absence of MTX for at least 6 days. MTX-
sensitive and resistant lines were then passaged into 60 mm
tissue culture dishes, and allowed to grow in MTX-free
medium. Prior to the attainment of confluence (late log
phase) medium was removed from the cells and replaced with
2 ml of EMEM plus 10% NBCS containing 30gM Fluo-
MTX. In addition the medium contained 301M each of
thymidine, glycine and hypoxanthine (Sigma) to protect the
cells from the inhibitory effect of Fluo-MTX on DHFR
(Kaufman et al., 1978). To demonstrate that Fluo-MTX was
binding to DHFR, M3000 cells were incubated in medium
containing all of the supplements described above, but in
addition 20gM free MTX was also included to compete with
Fluo-MTX for DHFR binding.
Cells were incubated for 22 h at 37'C in 5% CO2 in the
dark. Cells were then rinsed and incubated with 5 ml of
EMEM plus 10% NBCS for 15 min at 37°C to allow efflux
of unbound Fluo-MTX before they were gently harvested,
washed and resuspended at about 2 x 106 cells ml ' in ice-
cold HBSS plus 2% NBCS, and samples were maintained on
ice prior to analysis for fluorescence at 488 nm using a
FACS. For each determination at least 10,000 viable cells
were run through the FACS. The mean linear fluorescence
reading obtained was proportional to the DHFR level.840 K. AFFLECK & M.J. EMBLETON
Results
Development ofMTX-resistant 791Tsublines
The stepwise selection procedure described in 'Materials and
methods' resulted in the establishment of four MTX-resistant
sublines of the 791T cell line, designated R120, R160E, R250
and R500. These were named according to the maximum
dose of MTX in ng ml-' in which the cells could be grown
continuously (e.g. R120 was grown in a maximum dose of
120 ngml-'). The R160E variant was grown in the absence
of MTX and TPA as soon as continuous growth in
160 ngml-' MTX was achieved in order to try to revert this
line to MTX-sensitivity.
When tested for sensitivity to MTX in a [75Se]seleno-
methionine incorporation assay it was found that all four of
the 791T variants were MTX-resistant relative to the parental
791T cell line by comparison of their IC50 values (Figure 1).
R120, R160E, R250 and R500 had respective IC50 values of
794, 630, 3800 and 10000 ngml-' in terms of MTX concent-
ration, which were 42.2, 33.5, 202.1 and 532 times higher
than the IC5o value of 18.8 ngml-' for the parental 791T
line. The degree to which the variants were resistant to MTX
was roughly proportional to the maximum concentration of
MTX in which they had been grown.
[3H]MTX uptake
The uptake of [3H]MTX by parental and MTX-resistant
791T lines at an extracellular MTX concentration of 1 gM is
shown in Figure 2. The MTX-resistant variants R120,
R160E, R250 and R500 were all significantly transport
deficient relative to parental cells but apart from the most
resistant variant R500, showed no statistically significant
difference from each other. The results shown are the mean
of four separate determinations carried out on different days.
Levels ofdihydrofolate reductase
The Fluo-MTX labelling method used to assess DHFR levels
in the parental and MTX-resistant 791T sublines was based
on the principle that Fluo-MTX binds stoichiometrically to
DHFR such that, when cells are analysed using a FACS
following incubation with Fluo-MTX, the level of fluor-
escence recorded should be proportional to the amount of
DHFR enzyme present in the cells. Furthermore, Fluo-MTX
is apparently transported into cells by passive diffusion and
not via the reduced folate/MTX-transport system (Assaraf et
al., 1989). Therefore, this is a valid method to use with cells
that are MTX-transport deficient.
Cells were incubated with 30JAM Fluo-MTX for 22 h at
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Figure 1 Cytotoxicity of MTX against osteogenic sarcoma 791T
sublines, tested by [75Se]selenomethionine micro-cytotoxicity assay
(Embleton et al., 1983). Each point is the mean of four replicates,
and SDs are shown where the symbol size is exceeded. The
sublines are MTX-resistant relative to the parental lines, in pro-
portion to the maximum concentration of MTX in which the
cells were grown. -0- 791T, -0- R120, -A- R160E, -O-
R250,-*
- R500.
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Figure 2 Uptake of [3H]MTX by MTX-resistant osteogenic sar-
coma 791T. Cells were incubated with 1 JAM [3H]MTX in Dulbec-
co's PBS, pH 7.2, at 37°C. Samples were removed at various time
points up to 60min, and incorporated radioactivity was
measured. Each point is the mean of four determinations carried
out on different days. Error bars indicate standard deviations.
-0- 791T, -A R120, -*- R160E, -O- R250, -*- R500.
37°C, and analysed at 488 nm on a FACS. A positive control
was included in the form of the Chinese hamster ovary cell
line M3000, a gift from Dr A. Kinsella, which was highly
resistant to MTX, and was known to overproduce DHFR.
The M3000 line was also incubated with 30OM MTX in the
presence and absence of 20JIM MTX as a competitor, to
confirm that the Fluo-MTX was binding to DHFR.
Figure 3 shows that there were no gross changes in DHFR
levels in the variant lines compared to their parental cell line
by this method. The M3000 line, which overproduces
DHFR, gave a mean linear fluorescence reading of 214.3.
Incubation of cells with 20JAM free MTX inhibited complete-
ly the binding of 30gM Fluo-MTX to DHFR, which was
possible since MTX is more efficient than Fluo-MTX at
binding DHFR (Gapski et al., 1975; Gaudray et al., 1986).
Investigation of extracts of the 791T lines by more conven-
tional spectrophotometric assays never indicated increased
DHFR concentrations. However, the extracts were found to
be inhibitory towards exogenous purified DHFR, so
biochemical assays were judged to be inappropriate for these
cell lines (unpublished results, K.A.).
Cytotoxicity ofMTX-HSA-79J T/36 conjugates
Several MTX-HSA-791T/36 conjugates prepared by the
method of Garnett and Baldwin (1986), were tested against
791T parental cells and MTX-resistant sublines.
The cytotoxicity of one of these conjugates, MHT6C1,
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Figure 3 Dihydrofolate reductase (DHFR) levels for osteogenic
sarcoma 791T parental and MTX-resistant cell lines. Cells were
incubated with 30JuM Fluo-MTX for 22 h at 37°C, and mean
linear fluorescence (MLF) values were determined by flow
cytometry. None of the 791T sublines overexpressed DHFR com-
pared to their respective parental cell lines. M3000 is a Chinese
hamster ovary cell line which overexpresses DHFR, and gave a
high MLF reading. M3000 was also incubated as above but also
in the presence of 20 JAM free MTX, which inhibited the binding
of Fluo-MTX to DHFR.
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against 791T parental and MTX-resistant cells is shown in
Figure 4a through Figure 4e.
The MHT6C1 conjugate was cytotoxic to 791T cells with
an IC5o with respect to MTX of 16 ng ml-' (Figure 4a), and
was as cytotoxic to the variants R120, R160E and R250 as it
was to parental cells, these variants giving ICo values of 8.6,
16.5 and 10.4 ng ml respectively (Figure 4a-Figure 4d). The
conjugate was, therefore, able to overcome the MTX-
resistance of the variants. These cytotoxicities were not due
simply to higher expression of the 791T/36-defined gp72
antigen by the MTX-resistant sublines, since by indirect
immunofluorescence techniques (see 'Materials and methods')
the level of expression of this antigen by the sublines was
high, but never higher than for parental 791T cells (Data not
shown). The R500 line was about 10 times more sensitive to
MHT6C1 than it was to free MTX with an ICo of
185 ngml-' in terms of MTX (Figure 4e), but it was not
possible to overcome totally the resistance observed using the
MTX-HSA-791T/36 conjugate. Several other similar con-
jugates resulted in comparable cytotoxicity against the 791T
variants (data not shown).
These conjugates were not cytotoxic to cells of the bladder
carcinoma line T24, which had the same properties ofgrowth
rate and MTX-sensitivity as 791T cells, but which expressed
less than 10% of the 791T/36-defined gp72 antigen level of
791T cells (data not shown). Similar results obtained by one
of us (MJE) were published by Garnett and Baldwin (1986).
Competitive effect offree antibody
In order to demonstrate formally that the cytotoxicity of the
conjugates was mediated by antibody-antigen interaction,
assays were carried out to determine the effect of competing
free 791T/36 antibody on the cytotoxicity of MHT6C1
against R120 cells. For this, a fixed concentration of
MHT6C1 or MTX was used which resulted in about 85%
inhibition of ['5Se]selenomethionine incorporation. These con-
centrations were 1 ig ml-' free MTX, and 32 ngml-' with
respect to MTX for the MHT6C1 conjugate. These doses
were added to R120 cells in the presence of increasing con-
centrations of free 791T/36 antibody, or 791T/48 antibody
(an antibody also raised against 791T cells, but which recog-
nises a different epitope). Figure 5a shows that free 791T/36
antibody had no effect on the cytotoxicity of 1 isg ml-' MTX
against R120 cells. However, this antibody progressively
blocked the cytotoxic effect of MHT6C1 on R120 cells,
giving complete inhibition at a ratio of about 25 free to 1
conjugated antibody molecule. It is important to note from
Figure 5a that antibody 791T/36 alone did not affect the
survival of the strongly antigen-positive R120 cell line, as
shown previously for 791T cells (Embleton et al., 1983).
The 791T/48 antibody had no effect on cell survival, or on
the cytotoxicity against R120 of either MTX or MHT6C1
conjugate (Figure Sb).
These data suggest that the cytotoxic effect of MTX-HSA-
791T/36 conjugates, such as MHT6C1, was via an antibody-
mediated mechanism of drug entry into the cell.
Parallel studies concerning the mode of action of these
MTX-HSA-791T/36 conjugates (data not shown) have given
further support to this proposal. Cocarboxylase (or thiamine
pyrophosphate, Sigma), a potent inhibitor of the reduced
folate/MTX transport system (Henderson & Zevely, 1983),
had no effect on the cytotoxicity of the MHT6C1 conjugate
against R120 cells, indicating that none of the cytotoxicity
observed was due to free drug released from the conjugate
extracellularly. Furthermore, by use of agents able to inhibit
lysosomal protein degradation (ammonium chloride (Oh-
kuma & Poole, 1978) and leupeptin (Seglen et al., 1979)), it
was shown that, once internalised, the MTX-HSA-791T/36
conjugates require lysosomal degradation to release free
MTX in order to exert their cytotoxic effect, also shown
previously for such conjugates (Garnett et al., 1985).
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Figure 4 Cytotoxicity of MTX and the MTX-HSA-791T/36 conjugate MHT6Cl on 791T parental a, and MTX-resistant 791T
sublines R120 b, R160E c, R250 d, and R500 e, measured by ["5SeJselenomethionine microcytotoxicity assay. Points at which the
cytotoxicity of MHT6C1 was significantly different to that of MTX as indicated (*P<0.05; **P<0.001; Student's t-test). The
conjugate was able to wholly or partially overcome the MTX resistance of the sublines. -0- MTX, --- MHT6C1.
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791T/36 antibody blocked the cytotoxicity of MHT6C
concentration-dependent manner, but did not affect the c
icity of MTX. Antibody alone was not cytotoxic to th
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Cytotoxicity ofbispecific antibody-targeted MTX
Since indirect conjugates are subject to some in vivo c:
problems (Pimm et al., 1987), interest has been sho%
alternative, two-stage approach to drug targetinj
bispecific antibodies. 516 is a bispecific antibody whic
nises both the 791T/36-defined gp72 antigen, and M
jugated to proteins, including HSA (HSA-MTX) (I
al., 1990). From Figure 6 it is seen that the cytoto)
HSA-MTX to 791T cells was markedly increased by;
of bispecific antibody, the response correlating with a
concentration, as observed previously by Pimm et al.
At the maximum concentration of antibody
(6.12gigml1l), uptake of [75Se]selenomethionine was
to 47% of that in the control untreated cells. A simil
was also observed for the MTX-transport deficient R
In fact, use of the 516 bispecific antibody and HS,
was more effective against R120 cells than against
791T cells, such that the dose of 516 resulting
inhibition of [75Se]selenomethionine was 2.15Ig rr
R120 cells compared to 4.64pgml'l for 7911
Presumably, following binding of the HSA-MTX
localised 516 antibody, the complex is internalis(
undergoes lysosomal degradation with release of fr
intracellularly, as do the MTX-HSA-791T/36 conju,
It would appear that the MTX-resistant R120 line
sensitive to 516-targeted HSA-MTX as were parent
cells; it would, therefore seem possible to overcome ti
port deficiency of the R120 line in vitro by usi
bispecific antibody-targeting approach.
Discussion
The potential therapeutic usefulness of monoclon
bodies to tumour associated antigens in targeting c
agents selectively to the tumour site has been the su
mucn researcn. 1ne cytotoxic agents mat nave Deen inves-
tigated include plant and bacterial toxins, such as ricin,
abrin, and diphtheria toxin (Thorpe & Ross, 1982), radionuc-
lides (Buchegger et al., 1988), enzymes (Bagshawe, 1987), and
conventional cytotoxic drugs, such as vindesine (Embleton et
al., 1983), methotrexate (Embleton & Garnett, 1985), and
daunomycin (Gallego et al., 1984). These agents have been
coupled to a variety ofmonoclonal antibodies either directly,
or indirectly via a carrier molecule.
In this laboratory, much work has been carried out on the
.1 .I ,- . - . .- r,_ - __v_ _e s___ synthesis and therapeutic potential of conjugates of drugs
and anti-tumour monoclonal antibodies (Embleton &
Garnett, 1985). A large proportion of this work has centred
on the use of the anti-folate drug methotrexate (MTX) and
the monoclonal antibody 791T/36, which was raised against
the human osteogenic sarcoma cell line, 791T (Embleton et
al., 1981), and recognises a 72,000 molecular weight glyco-
protein (gp72) on the cell surface (Price et al., 1983).
One of the major problems of cancer chemotherapy is the
development of drug resistance. This is a commonly occurr-
ing phenomenon in tumours treated with the anti-folate drug
100 MTX. It was therefore felt that, as part of the study of
MTX-monoclonal antibody conjugates in cancer chemo-
therapy, the effects of such conjugates on MTX-resistant
on the variant cell lines should be investigated.
esistant Four MTX-resistant sublines of the 791T osteogenic sar-
( and coma cell line were derived which showed different degrees of
crms of MTX-resistance, proportional to the maximum dose of MTX
iS error in which they had been grown. They were all significantly
iich the MTX-transport deficient, and did not overproduce DHFR. A
or con- number of approaches to overcoming MTX-resistance due to
t). Free defective MTX-transport have been assessed previously.
'1 in a However, the potential of monoclonal antibody-targeted Sytotox- MTX for by-passing the defective MTX transport system had
ie cells. not yet been investigated.
Le. For the initial studies, the cytotoxicity towards the paren-
tal and MTX-resistant 791T lines of conjugates of MTX
linked to the 791T/36 antibody via a human serum albumin
(HSA) carrier (791T/36-HSA-MTX) was investigated. The
use of the carrier allowed the synthesis of conjugates with
learance high molar substitution ratio (e.g. 41.0mols MTX per mol
vn in an antibody for MHT6C1). All of the 791T variants expressed
g using high levels of the gp72 antigen. The conjugates were
h recog- cytotoxic to 791T cells, but showed no toxicity to T24 cells
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tance was overcome partially, suggesting that mechanisms of
resistance other than transport deficiency may have been
involved.
Investigation of the mode of action of these conjugates,
using the R120 MTX-resistant 791T variant as an example,
showed that they required antibody binding for cytotoxicity,
suggesting that the conjugates were able to overcome resis-
tance in the transport deficient cells by allowing drug to enter
via an antibody-mediated mechanism, so by-passing the
defective MTX carrier.
These studies suggested that in vitro it was possible to
overcome totally or partially the resistance to MTX of
variants of the cell line 791T using monoclonal antibody-
HSA-MTX conjugates. However, antibody-carrier-drug con-
jugates of this type have poor properties of biodistribution in
vivo (Pimm et al., 1987), and poor tumour localisation and
penetration due mainly to their larger size, and therefore the
in vitro ability of these conjugates to overcome totally MTX-
transport deficiency may not be realised in vivo.
An alternative approach was tested, using the 516
bispecific antibody (which recognises both MTX and 791T/36
antibody (Pimm et al., 1990), to target highly substituted
HSA-MTX to the MTX-resistant 791T subline R120; by
pre-targeting the antibody to the tumour site prior to the
administration of HSA-MTX some of the in vivo biodistribu-
tion problems associated with the indirect conjugates may be
avoided. It was found that in vitro the 516 antibody was able
to augment the cytotoxicity of HSA-MTX to R120 cells as
efficiently as for parental 791T cells, but it was not possible
to overcome totally the resistance of this line by this app-
roach. However, this could have been due to the relatively
low affinity of the 516 antibody (Pimm et al., 1990), and if a
more suitable antibody could be produced perhaps greater
cytotoxicity could be achieved.
The studies described here have shown that antibody-
targeting approaches to chemotherapy could totally or par-
tially overcome the MTX-transport deficiency of the 791T
sublines in vitro. However it must be stressed that these
investigations have demonstrated the feasibility of the princi-
ple, and do not claim to have clinical applications using the
ragents described. However, it is hoped that if more suitable
immunologically targeted reagents could be developed this
approach may have some therapeutic potential in tackling
the problem of acquired drug resistance by tumour cells
during cancer chemotherapy due to defective drug transport
mechanisms.
This work was supported by the Cancer Research Campaign.
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